Streptococcus pneumoniae (pneumococcus) is a major cause of bacteremia, pneumonia, meningitis, and otitis media in the United States. A 7-valent pneumococcal conjugate vaccine (PCV7) was licensed in the United States during 2000 for routine use in children ,2 years of age and for use in children aged 2-5 years with particular high-risk conditions. Before vaccine introduction, serotypes included in PCV7 accounted for 80% of cases of invasive IPD in US children aged ,5 years and for 50% of cases in persons aged $6 years [1] . PCV7 has been shown to be 96% effective against IPD due to vaccine serotypes in healthy children [2] .
After vaccine introduction, rates of IPD due to vaccine serotypes decreased significantly among children in the vaccine target age group and among nonvaccinated children and adults. These indirect effects of vaccination have been attributed to reduced nasopharyngeal colonization among vaccinated children and reduced transmission from children to adults [3] [4] [5] . Studies conducted in such geographically diverse locations as Alaska, Utah, Texas, Massachusetts, California, and Arizona have consistently shown a decrease in rates of IPD due to PCV7 serotypes [6] [7] [8] [9] [10] [11] [12] . Although PCV7 has been highly successful, several studies have documented an increase in the rate of nasopharyngeal carriage of and infections with serotypes not included in the vaccine [6] [7] [8] ; in the United States, serotype 19A has been largely responsible for the increase [7, 13] .
Rates of IPD due to non-PCV7 serotypes have increased to a much greater extent among Alaska Natives and in Texas, compared with rates in Utah and Massachusetts [7] [8] [9] [10] 12] . In contrast, rates in California and Arizona have not changed [6, 11] . The objective of our evaluation was to determine whether widespread use of PCV7 had different effects on rates of IPD and serotype distribution in 8 geographic areas under continuous surveillance since 1998 and, if so, to hypothesize why these differences exist.
METHODS

IPD Case Identification
Cases of IPD were identified through the Centers for Disease Control and Prevention (CDC) Active Bacterial Core surveillance (ABCs), an active population-based, laboratory-based surveillance network. IPD was defined as the isolation of S. pneumoniae from a normally sterile body site (eg, cerebrospinal fluid or blood) in a surveillance area resident during 1 January 1998 through 31 December 2009. Surveillance officers conducted laboratory audits periodically to ensure the completeness of reporting. 
Laboratory Methods
Serotyping of pneumococcal isolates using type-specific antiserum samples and the Quelling reaction was conducted at the CDC (Atlanta, GA) and at the Minnesota Department of Health (Saint Paul, MN). We grouped individual serotypes into the following mutually exclusive groups: PCV7-types (4, 6A, 6B, 9V, 14, 18C, 19F, and 23F), 19A, and all others. Serotype 6A was included as a PCV7 serotype on the basis of data demonstrating PCV7 cross-protection against serotype 6A [2] . Serotype 19A was analyzed separately, because we knew that there was no activity of PCV7 against serotype 19A and that this serotype has emerged as the most common nonvaccine serotype in the postvaccine era [2] .
Statistical Analysis
We calculated IPD incidence rates by surveillance site, serotype group, age, and year. Because isolates were not available for all cases, we assumed the same serotype distribution among cases for which serotype information was available for each site, age group, and year. To summarize the trends in IPD over time, the mean prevaccination rates in 1998 and 1999 were subtracted from the postvaccination rate in 2009 for each age-site stratum to calculate the rate difference; relative risks and percent changes ([relative risk21] 3 100) with 95% confidence intervals (CIs) were also calculated for each of the comparisons in our analysis, including stratifications by serotype group, age, and site. Calculations and statistical analyses were performed using SAS, version 9.1.3 (SAS Institute).
RESULTS
The total population under surveillance increased from a mean of 16,605,980 persons during 1998-1999 to 19,319,550 in 2009. Among residents from the ABCs sites in 2009, 4% were from California, 19% were from Connecticut, 27% were from Georgia, 14% were from Maryland, 15% were from Minnesota, 6% were from New York, 8% were from Oregon, and 8% were from Tennessee. During 1998-1999, 8094 cases of IPD were reported. An additional 27,269 cases were identified during 2000-2009. Among the 35,363 IPD cases, 31,534 (89%) had isolates available for serotyping.
Site-and Age-Specific Changes by Serotype
All Serotypes During the pre-PCV7 baseline period 1998-1999, the IPD incidence across the sites for all age groups combined was 19-29.9 cases/100,000 population. After vaccine introduction in 2000, rates of IPD decreased dramatically ( Figure 1A ) and, in 2009, were 11.2-18.0 cases/100,000 population ( Table 1 ). The overall reduction for all sites combined was 10.9 cases/100,000 population, with significant decreases across all sites (range, 27%-55.9%) ( Table 1) . California, Georgia, and Maryland had the highest rates before vaccine introduction and the greatest absolute rate reductions after vaccine introduction. Tennessee had the highest absolute rate in 2009, driven by increases in rates of serotype 19A and all other nonvaccine serotypes (Table 1, Figure 1A) .
Reductions in overall IPD rates between the pre-PCV7 period and 2009 among children aged ,5 years were 35.7-117.2 cases/100,000 population across the sites. Rate reductions also occurred among unvaccinated older children and adults at most surveillance sites (Figure 2A ). Absolute rate reductions in the $65 year age group were 17.2-29.7 cases/100,000 population. However, in Tennessee, there was an increase of 12.3 cases/ 100,000 population in the 50-64 year age group that was driven by an increase in 19A and non-PCV7 IPD rates.
PCV7 Serotypes
The incidence of PCV7-type IPD for all ages combined was 12-21.4 cases/100,000 population across the sites during the prevaccination baseline period (Table 1, Figure 1B) . After vaccine introduction, geographic variation was nearly eliminated. Rates of PCV7 type disease at all sites decreased to ,2 cases/100,000 population, representing statistically significant reductions of 92%-98% (Table 1) .
Rates of PCV7-type IPD also decreased across all age groups at all sites ( Figure 2B ). The greatest PCV7-type IPD reductions were seen in the vaccine target age group, resulting in 98%-100% reductions in overall IPD rates among children ,5 years of age ( Figure 2B ). Rate reductions in this age group were 46.5-126 cases/100,000 population across the sites and were most pronounced in Georgia ( Figure 2B ). The next greatest decrease in PCV7-type IPD rates was seen in the $65 year age group, with an overall reduction of 35.3 cases/100,000 population, which was most pronounced in Maryland (43.6 cases/100,000 population). (Table 1) . Absolute increases in incidence were 0.9-2.8 cases/ 100,000 population, with relatively large 95% CIs. Modest increases in rates of serotype 19A IPD were observed for most age groups ( Figure 2C ). The greatest increase in 19A rates was seen in the ,5 year age group (7.8 cases/100,000 population). The greatest increases occurred in Tennessee and Maryland (11.2 cases/100,000 population). All Other Serotypes Changes in rates of IPD caused by all other serotypes were less consistent across sites. Rates before vaccine introduction were 6.3-10.3 cases/100,000 population. Oregon and Tennessee had the greatest rate increases in all other serotypes (range, 72%-81.8%) ( Table 1) , but absolute rate increases were small ( Figure 2D ). Overall rates remained relatively unchanged in California, with a nonsignificant reduction of 0.4 cases/100,000 population (Table  1) , but varied by age group ( Figure 2D ).
Changes in rates of IPD due to all other serotypes also varied by age group at other sites ( Figure 2D ). For the ,5 year age group, Minnesota experienced a small rate decrease, whereas other sites experienced rate increases. Rates of IPD due to all other serotypes decreased in the 5-17 and the 50-64 year age groups in California and increased at all other sites. The greatest rate increases were seen in the 50-64 and .65 year age groups, with the greatest increase in persons aged 50-64 years in Tennessee (16.4 cases/100,000 population). Data from Tennessee were more closely evaluated to determine why overall IPD rates have been increasing among persons aged 50-64 years. There was no clustering of cases reported at the county or hospital level that would suggest a change in clinical practices. There were no clusters of individual serotypes suggestive of an outbreak. Although the distribution of all other serotypes was generally similar across the sites, serotype 12F was more common in Tennessee. The significance of this finding is unclear. No changes in case ascertainment practices in Tennessee were reported.
The rate reduction in overall (10.9 cases/100,000 population) and PCV7-type (15.9 cases/100,000 population) IPD exceeded the increase in IPD rates caused by 19A (1.9 cases/100,000 population) and all other serotypes (3.1 cases/100,000 population) at all sites for all ages combined (Table 1 ). All sites experienced at least a 27% reduction in IPD rates.
DISCUSSION
PCV7 has been highly effective at reducing PCV7-type IPD across the 8 ABCs sites included in this analysis, consistent with previous findings [6] [7] [8] [9] [10] [11] [12] . The similar 4-dose PCV7 coverage rates across the ABCs states (range, 79%-91%) among children 19-35 months of age may help explain the consistent trends in IPD rates that we observed (www.cdc.gov/vaccines/stats-surv/ imz-coverage.htm) [14] . The reduction in PCV7-type IPD rates in the ,5 years age group was expected because this age group both had the highest rates of disease before vaccination and was the target group for vaccination.
Although reductions in PCV7-type IPD rates were quite consistent across sites, increases in rates of IPD due to non-PCV7 serotypes, including serotype 19A, were more variable, despite similar rates of overall IPD evident before PCV7 introduction ( Figure 1A ). These differences may be related to a variety of factors. First, the modest differences in IPD rates before PCV7 introduction may reflect important differences in the underlying populations, such as differences in racial distributions; the prevalence of AIDS, which substantially increases the risk of IPD; differences in socioeconomic status; and differences in risk factors, such as smoking or prevalence of influenza infection [15] [16] [17] . The prevalence of chronic illness may vary by site, and patients with chronic illness may be more likely to have blood cultures performed. Thus, clinical practices, such as blood culture, among different patient groups may differ by site, leading to variable identification of IPD cases. Since vaccine introduction, the proportion of antibiotic-resistant serotype 19A isolates has increased significantly [18] [19] [20] ; therefore, differences in rates across sites may be related to differing antimicrobial use [21, 22] . In a recent study using IMS Health National Sales Perspectives Data, antibiotic prescription rates per capita in the southern United States were significantly higher than rates in the western United States [23] . It is possible that certain clones of serotype 19A are more prevalent in some parts of the country. Increasing rates of IPD due to serotype 19A and all other serotypes may be of greater concern in particular sites. However, the significant reductions in IPD rates conferred by PCV7 at all sites continue to outweigh the relatively small rates of IPD due to other serotypes that we have observed.
There are limitations to this analysis. First, we were unable to adjust for differences in age and race. Because data on risk factors (eg, underlying conditions, smoking prevalence, and influenza incidence) were not available at the level of the catchment area, we were unable to account for these factors in our analysis. Second, small case counts at several sites resulted in wide 95% CIs for percent changes in IPD rates (especially for serotype 19A). Third, the population for which vaccine coverage was determined is not necessarily the same as the ABCs population, limiting the ability to make a true comparison of vaccine coverage among surveillance sites. Fourth, the demographic characteristics of populations living in ABCs sites differ from those of the overall US population.
On 24 February 2010, a 13-valent pneumococcal conjugate vaccine (PCV13) was licensed by the US Food and Drug Administration for prevention of IPD caused by 7 serotypes in PCV7 plus 6 additional serotypes, including serotype 19A. Continued surveillance across different geographic locations to monitor changes in rates of disease due to non-PCV13 vaccine type will be crucial.
